The quest to reverse age-related diseases just got a significant financial boost, with Life Biosciences announcing a $120.0M Series d funding round. The biotech company, which specializes in epigenetic restoration, is the sole holder of intellectual property for its technology and has already secured FDA approval to advance it into human clinical studies.
Life Biosciences' platform has shown promise in preclinical models, demonstrating the potential to rejuvenate cells and restore function across various age-related conditions. While its initial clinical trial targets optic neuropathies, the company's science aims to bring broader therapeutic benefits to patients.
